PPA1

Inorganic pyrophosphatase · Q15181 · PPA1 on Sugi Atlas →

0 patent compounds predicted against PPA1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PPA1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Alendronate Versus Denosumab in Kidney Transplant Patients PHASE2/PHASE3COMPLETED
The Prevention of Systemic Ectopic Mineralization in Pseudoxanthoma Elasticum PHASE3RECRUITING
Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP) PHASE2WITHDRAWN
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma PHASE1/PHASE2RECRUITING
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC) PHASE2COMPLETED
Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease PHASE2COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults PHASE1RECRUITING
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency PHASE1RECRUITING
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) nanCOMPLETED
Studying Phosphorus Metabolism nanCOMPLETED
Exome Sequencing for Atypical Femoral Fractures nanCOMPLETED
Evaluation of ENPP1 Expression and Immune Response in Bladder Cancer Patients nanCOMPLETED
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism nanNOT_YET_RECRUITING
Natural History of GACI With or Without ARHR2 or PXE nanUNKNOWN
99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis nanCOMPLETED
Sulphate Accumulation in Prostate nanCOMPLETED
Tissue-nonspecific Alkaline Phosphatase in Phosphate and Pyrophosphate Homeostasis. nanCOMPLETED
CHOPXE - Analysis of Choriocapillaris Flow Deficits in Patients With Pseudoxanthoma Elasticum nanRECRUITING
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain nanCOMPLETED
Study of People With Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2) nanCOMPLETED
Biomarker for Hypophosphatasia Disease (BioHypophos) nanWITHDRAWN
Longitudinal Assessment of Atypical Tripeptidyl Peptidase 1 Enzyme Deficiency Patients nanACTIVE_NOT_RECRUITING
Hypophosphatemic Rickets in Norway nanUNKNOWN
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression nanCOMPLETED
Characterisation of Adult-Onset Hypophosphatasia nanCOMPLETED
Diagnostic Rentability of Screening for Associated Conditions in Calcium Pyrophosphate Deposition Disease Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PPA1 binder may also engage these)

ProteinNameSimilarity
P37980 1.000 P37980 →
Q5R8T6 1.000 Q5R8T6 →
Q4R543 1.000 Q4R543 →
Q9D819 1.000 Q9D819 →
Q757J8 0.997 Q757J8 →
P00817 0.996 P00817 →
Q8SR69 0.995 Q8SR69 →
Q6MVH7 0.995 Q6MVH7 →
Q5B912 0.995 Q5B912 →
Q6FRB7 0.995 Q6FRB7 →
O13505 0.995 O13505 →
P13998 0.995 P13998 →
Q93Y52 0.994 Q93Y52 →
Q6C1T4 0.994 Q6C1T4 →
Q6BWA5 0.994 Q6BWA5 →
P28239 0.994 P28239 →
Q9C0T9 0.993 Q9C0T9 →
P83777 0.993 P83777 →
Q9Z6Y8 0.993 Q9Z6Y8 →
P19117 0.993 P19117 →
O77460 0.993 O77460 →
P87118 0.992 P87118 →
Q91VM9 0.992 Q91VM9 →
Q9H2U2 0.991 Q9H2U2 →
Q9PLF1 0.990 Q9PLF1 →
O13434 0.989 O13434 →
Q821T4 0.989 Q821T4 →
B0B8Z8 0.989 B0B8Z8 →
Q95032 0.987 Q95032 →
Q54PV8 0.987 Q54PV8 →